London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Laser in situ keratomileusis to correct different types of astigmatism using Schwind Amaris 750s Laser

Poster Details

First Author: N.Kara TURKEY

Co Author(s):    O. Baz   E. Ozgurhan   A. Agca   E. Bozkurt   A. Demirok  

Abstract Details

Purpose:

To evaluate the efficacy and safety of LASIK to correct different types of astigmatism using Schwind Amaris 750S Laser

Setting:

Department of Ophthalmology, Gaziantep University School of Medicine, Gaziantep, Turkey and Beyoglu Eye Training and Research Hospital, Department of Ophthalmology, Istanbul, Turkey.

Methods:

In this retrospective case series, 140 eyes of 140 patients who underwent LASIK treatment for astigmatism were evaluated. The patients were divided into 3 groups based on the types of astigmatism: simple myopic astigmatism (SMA) (n=30), compound myopic astigmatism (CMA) (n=67), and mixed astigmatism (MA) (n=43). The efficacy and safety,of treatment were assessed at 6 months after the treatment.

Results:

At postoperative 6 months, the percentage of mean spherical equivalent of within ±0.50 D was 100% in eyes with SMA, 88.1% in eyes with CMA, and 90.7% in eyes with MA. The percentage of postoperative UCVA of 20/20 or better was 93.3% in eyes with SMA, 70.2% in eyes with CMA, and 34.9% in eyes with MA. The percentage of postoperative BCVA of unchanged or gained ≥1 lines was 90% in eyes with SMA, 80.6% in eyes with CMA, and 83.7% in eyes with MA.

Conclusions:

The findings of study revealed that LASIK seems to be more effective and safer in simple myopic astigmatism than compound myopic astigmatism and mixed astigmatism.

Financial Disclosure:

NONE

Back to Poster listing